Angiotensin‐Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New‐Onset Atrial Fibrillation After Acute Myocardial Infarction
- Received November 26, 2016
- Accepted January 19, 2017
- Originally published March 20, 2017.
- Gorav Batra, MD ()*,1,2;
- Lars Lindhagen, PhD1;
- Pontus Andell, MD, PhD3,4;
- David Erlinge, MD, PhD3,4;
- Stefan James, MD, PhD1,2;
- Jonas Spaak, MD, PhD5;
- Jonas Oldgren, MD, PhD1,2
- 1Uppsala Clinical Research Center, Uppsala, Sweden
- 2Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
- 3Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden
- 4Skåne University Hospital, Lund, Sweden
- 5Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden
- ↵*Correspondence to:
Gorav Batra, MD, Uppsala Clinical Research Center, Uppsala Science Park, MTC, Dag Hammarskjölds väg 14B, Uppsala 752 37, Sweden. E‐mail:
- © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Swedish Foundation for Strategic ResearchKF10‐0024